Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Traders are speculating that Johnson & Johnson could acquire Sellas Life Sciences, citing J&Js oncology ambitions and Sellass cancer-drug pipeline ahead of the REGAL trial readout. The rumored deal is unconfirmed, and the community also names other potential buyers.

ICPs recent rebound has sparked breakout talk, with traders watching whether momentum can clear nearby resistance after repeated rejections. The community is split between optimism about the move and ICPs decentralized-compute and AI-infrastructure thesis, and frustration over weak follow-through, lagging performance, and adoption still needing to prove itself.

GameStops rejected eBay takeover bid and its roughly 9.8% stake are driving attention, with traders debating whether Ryan Cohen will renew the bid, pursue influence or a partnership, or step back. Speculation about the deals path is mixed with reactions to eBays share moves and its standalone business prospects.

Avis Budgets earnings disappointment and heavy debt are fueling bearish talk about further declines and financial risk, while traders also debate whether the stock could repeat its earlier short squeeze. The conversation reflects sharp volatility and a split between fundamental concerns and squeeze speculation.

Traders are speculating that AbbVie could acquire Sellas around Sellass REGAL AML Phase 3 readout, though the buyout talk is unconfirmed. Other posts point to AbbVies breakout and recent highs as signs of bullish momentum.

Elevated refining margins amid tight diesel and other refined-fuel supplies are driving attention to MPC and its peer refiners, with traders highlighting the sectors repeated highs. The rally has also prompted profit-taking and debate over whether margins can stay elevated, particularly amid valuation concerns and possible policy changes that could affect fuel exports.

Upcoming MSToronto presentationsespecially late-breaking initial Phase 1 azer-cel findings in progressive MS, alongside BRIUMVI trial dataare driving attention. Traders view the late-breaking slot as encouraging but not proof of positive results, while also watching for the later subcutaneous BRIUMVI readout; buyout talk remains speculative.

ENAs rally is drawing attention alongside traders bullish discussion of Ethenas USDe growth and a reported Standard Chartered outlook; some also point to the approved fee-switch buyback framework, which would depend on USDe reaching its supply trigger before purchases begin. Bulls see adoption and potential buybacks supporting ENAs value, while others remain wary of token supply, unlocks, and pullbacks.

PEPE is drawing attention for a modest bounce after an extended stretch of weakness, but traders describe price action as largely sideways around the 4 level. Some are watching for a bullish breakout, while others warn the bounce could fade and focus on resistance near 5.

Bullish analyst coverage has renewed attention on BitGos institutional crypto-custody and infrastructure business. Traders see the shares as undervalued and tied to a crypto recovery, while skeptics point to past earnings disappointments and BTGOs tendency to lag Bitcoin and peer stocks.